- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ProQR Therapeutics NV (PRQR)
Assess today's live ProQR Therapeutics NV (PRQR) share price, performance and insights using our live NASDAQ: PRQR stock exchange data.
Analyse the historical data and ProQR Therapeutics NV share price performance charts on this page. Our technical summary section provides analysis on ProQR Therapeutics NV share price buy/sell indicators using real-time data (or discuss the ProQR Therapeutics NV (PRQR) stock price today with other investors in the ProQR Therapeutics NV NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ PRQR share price (ISIN: NL0010872495) to enhance your trading decisions with our free investment tools and resources.
What Is the ProQR Therapeutics NV Share Price Today?
The ProQR Therapeutics NV share price today is 1.930.
What Is the Stock Symbol for ProQR Therapeutics NV
The stock symbol (or 'ticker') for ProQR Therapeutics NV is "PRQR."
What Stock Exchange Does ProQR Therapeutics NV Trade On?
ProQR Therapeutics NV is listed and trades on the NASDAQ stock exchange.
Is ProQR Therapeutics NV a Good Stock to Buy?
Determining whether ProQR Therapeutics NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and ProQR Therapeutics NV share price performance charts on this page. Our technical summary section provides analysis on ProQR Therapeutics NV share price buy/sell indicators using real-time data (or discuss the ProQR Therapeutics NV (PRQR) stock price today with other investors in the ProQR Therapeutics NV NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ PRQR share price (ISIN: NL0010872495) to enhance your trading decisions with our free investment tools and resources.
What Is the ProQR Therapeutics NV Share Price Today?
The ProQR Therapeutics NV share price today is 1.930.
What Is the Stock Symbol for ProQR Therapeutics NV
The stock symbol (or 'ticker') for ProQR Therapeutics NV is "PRQR."
What Stock Exchange Does ProQR Therapeutics NV Trade On?
ProQR Therapeutics NV is listed and trades on the NASDAQ stock exchange.
Is ProQR Therapeutics NV a Good Stock to Buy?
Determining whether ProQR Therapeutics NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
1.930
-0.010(-0.52%)
Closed·
After Hours
1.9300.000(0.00%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.920
1.970
52 wk Range
1.070
4.620
PRQR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PRQR is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.9201.970
52 wk Range
1.0704.620
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PRQR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
8.875
Upside
+359.84%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Proqr Thera receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Proqr Thera receives Investment Bank Analyst Rating Update
- Investing.com
Pro
ProQR Therapeutics NV Company Profile
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
ProQR Therapeutics NV SWOT Analysis
RNA Editing Pionee | ProQR Therapeutics leads with Axiomer platform, targeting genetic drivers of MASH and cholestatic diseases, positioning for potential market leadership |
Pipeline Potential | Explore ProQR's promising candidates, including AX-0810 for cholestatic diseases and EON AX-2911 for MASH, with clinical trials set to begin 2024-2026 |
Financial Stability | Learn about ProQR's $103 million cash position, providing runway into mid-2026, and efficient cost management supporting ambitious development timeline |
Market Opportunity | Analysts set price targets from $4 to $15 per share, reflecting confidence in ProQR's approach to addressing significant unmet medical needs in MASH and cholestatic diseases |
Compare PRQR to Peers and Sector
Metrics to compare | PRQR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPRQRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.8x | −2.1x | −0.5x | |
PEG Ratio | 3.39 | 0.05 | 0.00 | |
Price/Book | 2.2x | 1.1x | 2.6x | |
Price / LTM Sales | 9.0x | 7.1x | 3.0x | |
Upside (Analyst Target) | 340.4% | 28.0% | 51.9% | |
Fair Value Upside | Unlock | 11.3% | 8.9% | Unlock |
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.875
(+359.84% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
-0.10 / -0.0928
Revenue / Forecast
4.52M / 3.90M
People Also Watch
FAQ
What Is the ProQR Therapeutics NV (PRQR) Share Price Today?
The live ProQR Therapeutics NV share price today is 1.93.
What Stock Exchange Does ProQR Therapeutics NV (PRQR) Trade On?
ProQR Therapeutics NV is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Ticker (Stock Symbol) for ProQR Therapeutics NV?
The stock symbol (also called a 'ticker') for ProQR Therapeutics NV is "PRQR."
What Is the Current ProQR Therapeutics NV Market Cap?
As of today, ProQR Therapeutics NV market capitalisation is 203.31M.
What Is ProQR Therapeutics NV's (PRQR) Earnings Per Share (TTM)?
The ProQR Therapeutics NV EPS -0.33 (Trailing Twelve Months).
When Is the Next ProQR Therapeutics NV Earnings Date?
ProQR Therapeutics NV's next earnings report will be released on 30 Jul 2025.
Is PRQR a Buy or Sell From a Technical Analyst Perspective?
Based on today's ProQR Therapeutics NV moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has ProQR Therapeutics NV Stock Split?
ProQR Therapeutics NV has split 0 times. (See the PRQR stock split history page for full effective split date and price information.)
How Many Employees Does ProQR Therapeutics NV Have?
ProQR Therapeutics NV currently has 166 employees.
What is the current trading status of ProQR Therapeutics NV (PRQR)?
As of 20 Jun 2025, ProQR Therapeutics NV (PRQR) is trading at a price of 1.93, with a previous close of 1.94. The stock has fluctuated within a day range of 1.92 to 1.97, while its 52-week range spans from 1.07 to 4.62.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.